Redmile Group, LLC Arvinas, Inc. Transaction History

Redmile Group, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$15.96 - $23.8 $2.41 Million - $3.59 Million	-150,955 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$13.55 - $23.79 $198,575 - $348,642	14,655 Added 10.75%	150,955 $2.23 Million
Q3 2018 Nov 14, 2018	BUY	$16.05 - $16.87 $2.19 Million - $2.3 Million	136,300 New	136,300 $2.3 Million

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.02B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Redmile Group, LLC with notifications on news.